International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.





James J. Leyden Professor of Dermatology and of Epidemiology; Vice Chair of Clinical Research (Dermatology); Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania
United States
Joel M. Gelfand, MD, MSCE, is the James J. Leyden Professor (with tenure) of Dermatology and Epidemiology, Director (founding) of the Center for Clinical Sciences in Dermatology, and Director of the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania Perelman School of Medicine. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of over 330 scientific publications cited over 35,000 times. He is Deputy Editor for Clinical Research of the Journal Investigative Dermatology (JID). He is the recipient of the American College of Epidemiology (ACE) 2023 Outstanding Contributions Award, the American Skin Association’s (ASA) Psoriasis Achievement Award, the Lady Barbara Colyton’s Award for Autoimmune Research, the National Psoriasis Foundation’s (NPF) Scientific Achievement Award, the American DermatoEpidemiology Network’s (ADEN) Founders award. He is an elected member of the American Society for Clinical Investigation. Dr. Gelfand is a member of the Board of Directors for the International Psoriasis Council (IPC) and the Medical Dermatology Society. He has given over ten named lectureships and keynote addresses, including the Society for Investigative Dermatology’s (SID) Eugene M. Farber lecture and the American Academy of Dermatology’s (AAD) Marion B. Sulzberger lecture. He has received grants from the National Institutes of Health (NIH), the United States Food and Drug Administration (FDA), the Patient-Centered Outcomes Research Institute (PCORI), and the NPF to support his independent research program. Dr. Gelfand is a dedicated mentor with over 20 MDs and PhDs, 12 of whom have received a master’s degree in clinical epidemiology, having spent at least one full year under his mentorship. Over 30% of dermatologists receiving K23 awards from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) over the last decade have been trainees in the Gelfand lab. His research redefined psoriasis as a systemic inflammatory disease that enhances the risk of cardiovascular events and premature mortality, resulting in changes in standard of care guidelines. His research and clinical practice aim to improve psoriasis patient outcomes in the skin and joints while lowering the risk of diabetes, cardiovascular disease, and mortality.
Last Updated:

Areas of Interest

I do investigator initiated research. I created a cohort in UK called iHOPE (the incident health outcomes and psoriasis events) study – this is a prospective study of 9000 patients in which we are evaluating the GPs estimate of body surface area and how this predict future health outcomes. I have also led a series of multi-center placebo controlled trials evaluating the impact of biologics, phototherapy, and apremilast on cardiovascular biomarkers and I am running a pragmatic trial (N=1050) to evaluate the comparative effectiveness of home vs office phototherapy for plaque or guttate psoriasis.

IPC Committees / Groups

Board Treasurer, Executive Committee, Fellowship Program Advisory Committee

Languages Spoken


Involvement with Other Organization(s)

Very active with the National Psoriasis Foundation (NPF); teaches at the United States Food and Drug Administration (FDA) annually.